BFT also activated NF-κB signalling, which increased CXCL1 secretion, leading to myeloid-derived suppressor cell recruitment and angiogenesis in the tumour microenvironment. Taken together, these findings uncover mechanisms through which ETBF facilitates GBC development, with potential promise as therapeutic targets to limit GBC progression.
Achieving negative margins through aggressive extended radical surgery may be a feasible treatment option in carefully selected patients; however, the oncological benefit remains to be validated. It emphasizes the critical role of multidisciplinary collaboration in diagnosis and treatment and adds new data to the limited literature on this rare disease.
P2, N=57, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: May 2026 --> May 2027
2 months ago
Trial completion date • Trial primary completion date
P2, N=58, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Jul 2027
2 months ago
Trial completion date • Trial primary completion date • Pan tumor
The presence of morules, which display nuclear β-catenin expression, places this lesion in the so-called BROCN family of tumors, which are believed to be hormonally driven. Further molecular studies are needed to explore the roots of their behavior.
This study establishes a fully automated CT-based deep learning pipeline for HER2 status prediction in unresectable GBC. Validation in larger, multi-institutional cohorts is warranted.